Máj- és epeúti rák: vizsgálatok itt: Kína
619 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleLiposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
- Where
- Nanjing
- Életkor
- 18 év to 80 év
- People
- 31
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07797816 - 1. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 21
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07557251 - No phaseTaking peopleHCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07795619 - 1/2. fázisNot yet taking people in KínaA Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
- Where
- Guangzhou, Shanghai, Wuhan
- Életkor
- 18 év and over
- People
- 112
- Run by
- Shanghai 6th People's Hospital
See details and how to joinNCT07632235 - No phaseNot yet taking people in KínaHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 2000
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT07780357 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Hefei, Hongcun, Jinan, Jining, Kunming, Lanzhou, Liaocheng, Nanchang, Nanning, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Wuxi, Xiamen, Xi’an, Xuzhou, Yantai, Yulin, Zhengzhou, Zibo
- Életkor
- 18 év and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - 2. fázisNot yet taking people in KínaShuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Xiang-Qian
See details and how to joinNCT07691645 - 4. fázisNot yet taking people in KínaA Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
- Where
- Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Zhai Wenlong
See details and how to joinNCT07790419 - 2. fázisTaking peopleHAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 36
- Run by
- Tongji Hospital
See details and how to joinNCT06187961 - 2. fázisTaking peoplePemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 154
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07786766 - No phaseTaking peopleLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Where
- Hefei
- Életkor
- 18 év to 75 év
- People
- 467
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07782632 - Korai 1. fázisTaking peopleA IIT Study of 177Lu-DOTA-SNA040
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- SmartNuclide Biopharma
See details and how to joinNCT07595237 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - No phaseTaking peoplePeg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 33
- Run by
- Jinling Hospital, China
See details and how to joinNCT07769827 - No phaseTaking peopleDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Where
- Beijing, Chongqing, Qingdao
- Életkor
- 18 év and over
- People
- 3000
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07070362 - 2. fázisTaking peopleGKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Where
- Beijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 48
- Run by
- Beijing Gene Key Life Technology Co., Ltd
See details and how to joinNCT07209813 - No phaseNot yet taking people in KínaPragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
- Where
- Shenyang
- Életkor
- 18 év and over
- People
- 40 000
- Run by
- Shengjing Hospital
See details and how to joinNCT07768085 - 1. fázisTaking peopleYMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07763301 - No phaseTaking peopleProtective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07760038 - 1/2. fázisNot yet taking people in KínaEvaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- Where
- Harbin
- Életkor
- 18 év and over
- People
- 288
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07761286 - 2. fázisTaking peopleLenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 320
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06904183 - No phaseTaking peopleThe Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 120
- Run by
- Fudan University
See details and how to joinNCT07159048 - 2. fázisNot yet taking people in KínaSHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
- Where
- Langfang
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07749859 - 3. fázisTaking peopleA Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 198
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07475026 - 2. fázisTaking peopleThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Where
- Wenzhou
- Életkor
- 18 év to 80 év
- People
- 134
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07381634